TWI877363B - 與延釋帕利哌酮可注射配製物相關之投藥方案（三） - Google Patents

與延釋帕利哌酮可注射配製物相關之投藥方案（三） Download PDF

Info

Publication number
TWI877363B
TWI877363B TW110116515A TW110116515A TWI877363B TW I877363 B TWI877363 B TW I877363B TW 110116515 A TW110116515 A TW 110116515A TW 110116515 A TW110116515 A TW 110116515A TW I877363 B TWI877363 B TW I877363B
Authority
TW
Taiwan
Prior art keywords
suspension
dose
paliperidone palmitate
administered
patient
Prior art date
Application number
TW110116515A
Other languages
English (en)
Chinese (zh)
Other versions
TW202222319A (zh
Inventor
斯里哈里 高波
拉賈 文卡塔蘇拉馬尼安
休伯特 提喬林
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75888043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI877363(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202222319A publication Critical patent/TW202222319A/zh
Application granted granted Critical
Publication of TWI877363B publication Critical patent/TWI877363B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110116515A 2020-11-30 2021-05-07 與延釋帕利哌酮可注射配製物相關之投藥方案（三） TWI877363B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119405P 2020-11-30 2020-11-30
US63/119,405 2020-11-30

Publications (2)

Publication Number Publication Date
TW202222319A TW202222319A (zh) 2022-06-16
TWI877363B true TWI877363B (zh) 2025-03-21

Family

ID=75888043

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110116515A TWI877363B (zh) 2020-11-30 2021-05-07 與延釋帕利哌酮可注射配製物相關之投藥方案（三）
TW114105894A TW202539685A (zh) 2020-11-30 2021-05-07 與延釋帕利哌酮可注射配製物相關之投藥方案(三)

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW114105894A TW202539685A (zh) 2020-11-30 2021-05-07 與延釋帕利哌酮可注射配製物相關之投藥方案(三)

Country Status (22)

Country Link
US (3) US11304951B1 (https=)
EP (2) EP4025188B1 (https=)
JP (2) JP7792959B2 (https=)
KR (2) KR102794804B1 (https=)
CN (1) CN116583270A (https=)
AU (2) AU2021386450B2 (https=)
CA (1) CA3203566A1 (https=)
DK (1) DK4025188T3 (https=)
ES (1) ES2973583T3 (https=)
FI (1) FI4025188T3 (https=)
HR (1) HRP20240074T1 (https=)
HU (1) HUE065573T2 (https=)
IL (1) IL303253A (https=)
LT (1) LT4025188T (https=)
MX (2) MX2023006366A (https=)
PL (1) PL4025188T3 (https=)
PT (1) PT4025188T (https=)
RS (1) RS65178B1 (https=)
SI (1) SI4025188T1 (https=)
SM (1) SMT202400077T1 (https=)
TW (2) TWI877363B (https=)
WO (1) WO2022111859A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7839162B2 (ja) 2020-11-30 2026-04-01 ヤンセン ファーマシューティカ エヌ．ベー． パルミチン酸パリペリドン製剤の再懸濁を確実にする方法
KR102794804B1 (ko) * 2020-11-30 2025-04-10 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
ES2981035T3 (es) 2020-11-30 2024-10-07 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada
MX2023006370A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802631A (zh) * 2009-10-30 2012-11-28 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
KR102318070B1 (ko) * 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
ES2456917T3 (es) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
RS65024B1 (sr) * 2015-04-07 2024-01-31 Janssen Pharmaceutica Nv Dozni režim za propuštene doze injektibilnih estara paliperidona sa produženim delovanjem
HK1254640A1 (zh) * 2015-06-19 2019-07-26 Janssen Pharmaceutica, N.V. 用於药物施用和混合的设备和方法及用於所述设备和方法的适当技术的训练
PL3723760T3 (pl) * 2017-12-14 2025-10-20 SpecGx LLC Jednoetapowy sposób mielenia w celu wytworzenia zmikronizowanych estrów paliperydonu
KR102794804B1 (ko) * 2020-11-30 2025-04-10 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802631A (zh) * 2009-10-30 2012-11-28 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Richard H Osborne et al., Health-related quality of life advantage of longacting injectable antipsychotic treatment for schizophrenia: a time trade-off study, Health and Quality of Life Outcomes 10:35. 2012 *

Also Published As

Publication number Publication date
SMT202400077T1 (it) 2024-03-13
WO2022111859A1 (en) 2022-06-02
AU2021386450A1 (en) 2023-07-13
SI4025188T1 (sl) 2024-03-29
AU2024204213B2 (en) 2026-02-26
US11304951B1 (en) 2022-04-19
US20260060986A1 (en) 2026-03-05
EP4025188A1 (en) 2022-07-13
JP2026027255A (ja) 2026-02-18
JP7792959B2 (ja) 2025-12-26
JP2023552329A (ja) 2023-12-15
KR20250053980A (ko) 2025-04-22
US20220249495A1 (en) 2022-08-11
KR102794804B1 (ko) 2025-04-10
MX2024009188A (es) 2024-08-06
PT4025188T (pt) 2024-02-29
AU2024204213A1 (en) 2024-07-11
HUE065573T2 (hu) 2024-06-28
RS65178B1 (sr) 2024-03-29
CA3203566A1 (en) 2022-06-02
LT4025188T (lt) 2024-03-12
TW202222319A (zh) 2022-06-16
AU2021386450B2 (en) 2024-03-21
EP4356966A3 (en) 2024-07-17
DK4025188T3 (da) 2024-03-04
HRP20240074T1 (hr) 2024-03-29
ES2973583T3 (es) 2024-06-20
CN116583270A (zh) 2023-08-11
IL303253A (en) 2023-07-01
PL4025188T3 (pl) 2024-06-17
EP4356966A2 (en) 2024-04-24
TW202539685A (zh) 2025-10-16
FI4025188T3 (fi) 2024-02-21
AU2021386450A9 (en) 2025-03-13
EP4025188B1 (en) 2024-01-10
MX2023006366A (es) 2023-08-07
KR20230116013A (ko) 2023-08-03

Similar Documents

Publication Publication Date Title
TWI877363B (zh) 與延釋帕利哌酮可注射配製物相關之投藥方案（三）
TWI838623B (zh) 與延釋帕利哌酮可注射配製物相關之投藥方案（二）
US12053474B2 (en) Dosing regimens associated with extended release paliperidone injectable formulations
KR20240052810A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
US12472184B2 (en) Dosing regimens associated with extended release paliperidone injectable formulations
EA049114B1 (ru) Схемы применения инъекционных составов с пролонгированным высвобождением палиперидона